达格列净联合二甲双胍对比二甲双胍单药治疗III级肥胖患者减重疗效的随机对照试验
该随机IV期临床试验计划纳入108例III级肥胖(BMI≥40 kg/m2)且合并糖尿病或糖尿病前期的18-60岁患者,随机接受二甲双胍850 mg每日两次单药或联合达格列净10 mg每日一次治疗。主要结局为减重效果,同时评估腰围、甘油三酯、血压及炎症因子变化。
要点
- 联合治疗可能为III级肥胖合并糖代谢异常患者提供额外减重获益。
- 研究纳入等待减重手术的患者,探索药物联合作为术前优化策略。
- 主要结局为体重变化,次要结局包括腰围、甘油三酯、血压和炎症因子。
核心结论
- 联合治疗是否优于单药减重尚待该试验结果验证。
研究设计与样本
- 随机IV期临床试验,计划纳入108例III级肥胖合并糖尿病或糖尿病前期患者。
- 随机分为二甲双胍850 mg每日两次组或联合达格列净10 mg每日一次组。
- 纳入标准为18-60岁、BMI≥40 kg/m2、合并糖尿病或糖尿病前期,排除使用胰岛素者。
- 研究设1个月导入期评估耐受性和依从性,随访至12个月。
关键数值与推荐
- 主要结局为体重变化,比较联合治疗与单药治疗的减重效果。
- 次要结局包括腰围、甘油三酯、血压和炎症细胞因子。
- 在基线和1、3、6、12个月记录人体测量学和生化变量。
- 在基线和术前或12个月(以先发生者为准)采集血清检测胰高血糖素、饥饿素、脂联素、抵抗素、白介素6和白介素10。
临床怎么用
- 若联合治疗有效,可能缩短等待减重手术时间并更好控制合并症。
局限性
- 该文为试验设计描述,尚未报告实际结果。
- 试验为回顾性注册(2019年5月29日)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mexico has one of the highest prevalence rates of obesity worldwide. New pharmacological strategies that focus on people with class III obesity are required. Metformin and dapagliflozin are two drugs approved for the treatment of diabetes. Beyond its effects on glucose, metformin has been suggested by some studies to result in weight loss. Therapy with dapagliflozin is associated with a mild but sustained weight loss in patients with diabetes. The primary outcome of the study is to determine if the combined treatment with dapagliflozin and metformin is more effective than monotherapy with metformin for weight loss in patients with class III obesity and prediabetes or diabetes who are awaiting bariatric surgery (including those patients who do have surgery). We also aimed to assess the effect of this combined treatment on waist circumference, triglycerides, blood pressure, and inflammatory cytokines. METHODS: This randomized phase IV clinical trial will include patients with diabetes or prediabetes who are between the ages of 18 and 60 years and exhibit grade III obesity (defined as body mass index ≥ 40 kg/m2). Patients using insulin will be excluded. Subjects will be randomized to one of two groups as follows: 1) metformin tablets 850 mg PO bid or 2) metformin tablets 850 mg PO bid plus dapagliflozin tablets 10 mg PO qd. The sample size required is 108 patients, which allows for a 20% dropout rate: 54 patients in the metformin group and 54 in the metformin/dapagliflozin group. All participants will receive personalized nutritional advice during the study. A run-in period of one month will be used to assess tolerance and adherence to treatment regimens. Anthropometric and biochemical variables will be recorded at baseline and at 1, 3, 6, and 12 months. A serum sample to determine glucagon, ghrelin, adiponectin, resistin, interleukin 6, and interleukin 10 will be collected at baseline and before surgery, or at 12 months (whatever happens first). Adherence to treatment and adverse and secondary events will be recorded throughout the study. An intention-to-treat analysis will be used. DISCUSSION: Forty-six percent of the patients in our Obesity Clinic have been diagnosed with prediabetes (32%) or diabetes (14%). The use of dapagliflozin in this population could improve weight loss and other cardiovascular factors. This effect could be translated into less time before undergoing bariatric surgery and better control of associated comorbidities. TRIAL REGISTRATION: Clinicaltrials.gov, ID: NCT03968224. Retrospectively registered on May 29, 2019.
引用
- Ferreira-Hermosillo A, Molina-Ayala MA, Molina-Guerrero D, et al. Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial. Trials. 2020. PMID: 32059692. doi:10.1186/s13063-020-4121-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。